Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Metabolism of BMS-986205 in Healthy Males
NCT03247283Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of linrodostat in cancer, sponsored by Bristol Myers Squibb. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Time of Last Quantifiable Concentration up to 28 days, Percent of Total Radioactivity Recovered in All Excreta up to 28 days and 4 more. Started Jul 2017; status: completed.
02
Drugs
linrodostat
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03247283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03247283.